Pangea Biomed is a Tel Aviv-based precision oncology biotech company building the world's most advanced multi-cancer response predictor. Founded by three leading cancer researchers and led by a team of computational biologists, bioinformaticians and data scientists, the company is coming out of stealth today with $7M in seed funding. For years, the medical community, cancer ... Continue reading "Why NFX Invested in Pangea Biomed, the Startup Matching Cancer Patients with the Right Therapies"